Acutus Medical, Inc.
OTCPK:AFIB Voorraadrapport
Marktkapitalisatie: US$2.4m
Acutus Medical Inkomsten in het verleden
Verleden criteriumcontroles 0/6 Acutus Medical is de winst gegroeid met een gemiddeld jaarlijks percentage van 45.1%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 13.2%. De inkomsten zijn gedaald met een gemiddelde van 40.6% per jaar.
Belangrijke informatie
98.8%
Groei van de winst per aandeel
Medical Equipment Groei van de industrie 8.9% Inkomstengroei -40.6% Rendement op eigen vermogen n/a Nettomarge -47.9% Laatste winstupdate 30 Jun 2024
Recente prestatie-updates uit het verleden
Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022) Apr 02
Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022) Nov 10
Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 03
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Toon alle updates
Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting May 18
Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index May 10
Acutus Medical Provides Non-Compliance Update May 04
Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
New minor risk - Shareholder dilution Apr 09
New major risk - Negative shareholders equity Apr 02
Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022) Apr 02
Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding Feb 24
Acutus Medical, Inc. Announces Board Changes Jan 18
Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower Dec 20 Acutus Medical, Inc. Announces Chief Executive Officer Changes
Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022) Nov 10
Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 03
Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market Nov 01
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023 Aug 09
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB) Jul 18
Acutus Medical, Inc. Announces Executive Changes Jul 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023 May 12
Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1) May 08
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 17
Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” Feb 07 Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
Price target increased to US$4.13 Jan 04
Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic Dec 22
Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5 Dec 20
High number of new directors Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations Nov 11
Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Nov 11
Acutus Medical Receives Non-Compliance Notice From Nasdaq Nov 07
High number of new directors Nov 02
Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System Oct 19
Acutus files for FDA approval of catheter ablation system AcQBlate Oct 18
Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc Aug 25 Acutus Medical, Inc. Announces Board Changes
Consensus forecasts updated Aug 18
Price target increased to US$3.38 Aug 13
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12
Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M Aug 11
Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29
Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan Jul 28 Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022
Acutus Medical sees Q2 revenue above consensus estimate Jul 21 Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C Jul 03
Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB). Jul 02
Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System Jun 28
Acutus Medical Receives Non-Compliance Notice from Nasdaq Jun 25
Consensus forecasts updated May 19 Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Price target decreased to US$3.50 Apr 27
High number of new directors Apr 27
Price target decreased to US$4.00 Apr 23
Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25% Apr 06
Consensus revenue estimates fall by 25% Apr 06
Full year 2021 earnings: EPS exceeds analyst expectations Apr 01
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc Feb 16
Acutus Medical, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 20
Independent Director recently bought US$151k worth of stock Nov 21
Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.95 loss in 3Q 2020) Nov 12
Price target decreased to US$16.40 Oct 22
Acutus Medical: A Name To Slowly Accumulate Sep 04
Acutus Medical, Inc. Provides Revenue Guidance for the Year 2021 Aug 15
Second quarter 2021 earnings released: US$1.02 loss per share (vs US$32.24 loss in 2Q 2020) Aug 14
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark Aug 12
Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price Jul 21
Acutus Medical, Inc. has completed a Follow-on Equity Offering in the amount of $77 million. Jul 16
Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021 Jul 14 Acutus Medical, Inc.(NasdaqGS:AFIB) dropped from Russell 3000E Value Index
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System May 28
Acutus Medical cleared to start atrial fibrillation IDE trial May 27
Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report May 15
First quarter 2021 earnings released: US$1.04 loss per share (vs US$25.83 loss in 1Q 2020) May 14
Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021 and Full Year Ending December 31, 2021 May 13
Full year 2020 earnings released: US$8.94 loss per share Mar 20 Acutus Medical, Inc. Appoints John Sheridan as A New Director
Acutus Medical, Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 05
Acutus Medical Appoints Duane Wilder as Chief Commercial Officer Mar 04
Hoe Acutus Medical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis OTCPK:AFIB Opbrengsten, kosten en inkomsten (USD Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Jun 24 12 -6 12 2 31 Mar 24 10 -10 13 3 31 Dec 23 7 -12 14 3 30 Sep 23 0 62 -3 -12 30 Jun 23 -2 55 0 -11 31 Mar 23 1 63 10 -4 31 Dec 22 3 29 20 3 30 Sep 22 16 -86 54 31 30 Jun 22 17 -94 60 34 31 Mar 22 17 -127 62 35 31 Dec 21 17 -118 64 37 30 Sep 21 15 -116 63 37 30 Jun 21 14 -119 63 36 31 Mar 21 10 -113 56 35 31 Dec 20 8 -102 50 33 30 Sep 20 7 -92 43 32 30 Jun 20 4 -93 35 30 31 Mar 20 4 -100 33 27 31 Dec 19 3 -97 27 23 31 Dec 18 2 -48 13 19
Kwaliteitswinsten: AFIB is momenteel verliesgevend.
Groeiende winstmarge: AFIB is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: AFIB is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 45.1% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van AFIB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: AFIB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 11.7% ).
Rendement op eigen vermogen
Hoge ROE: De schulden van AFIB zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
